Glaukos inks exclusive license with RevOpsis for RO-104
Glaukos said it has entered an exclusive licensing agreement with RevOpsis Therapeutics to develop and commercialize RO-104 for retinal diseases.
Story updates
11:01:08 AM UTC
SquawkNews
Glaukos announced an exclusive license with RevOpsis to develop and commercialize RO-104 for multiple retinal diseases and secured exclusive rights to the RevMod platform for up to four additional retinal biologic candidates. Financial terms were not disclosed.Material DetailsContext by AI AnalystT…